From Wikipedia, the free encyclopedia
Chemical compound
Avadomide is an experimental
cereblon E3 ligase modulator, or
thalidomide analog studied to see if it is effective against cancer.
[1]
[2]
[3]
[4]
[5]
[6]
-
^ Nishi, Hidemi; Gotoh, Kunihito; Tomimaru, Yoshito; Kobayashi, Shogo; Sasaki, Kazuki; Iwagami, Yoshifumi; Yamada, Daisaku; Akita, Hirofumi; Asaoka, Tadafumi; Noda, Takehiro; Takahashi, Hidenori; Tanemura, Masahiro; Doki, Yuichiro; Eguchi, Hidetoshi (October 2023).
"Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma". Cancer Chemotherapy and Pharmacology. 92 (4): 303–314.
doi:
10.1007/s00280-023-04531-w.
PMC
10435408.
PMID
37491611.
-
^ Nastoupil, Loretta J.; Kuruvilla, John; Chavez, Julio C.; Bijou, Fontanet; Witzig, Thomas E.; Santoro, Armando; Flinn, Ian W.; Boccomini, Carola; Kenkre, Vaishalee P.; Corradini, Paolo; Isufi, Iris; Andorsky, David J.; Klein, Leonard M.; Greenwald, Daniel R.; Sangha, Randeep; Shen, Frank; Hagner, Patrick; Li, Yan; Dobmeyer, Juergen; Gong, Nian; Uttamsingh, Shailaja; Pourdehnad, Michael; Ribrag, Vincent (May 2022).
"Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma". EJHaem. 3 (2): 394–405.
doi:
10.1002/jha2.394.
PMC
9175947.
PMID
35846031.
-
^ Heim, Christopher; Hartmann, Marcus D. (1 March 2022).
"High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system". Acta Crystallographica Section D Structural Biology. 78 (3): 290–298.
Bibcode:
2022AcCrD..78..290H.
doi:
10.1107/S2059798322000092.
PMC
8900816.
PMID
35234143.
-
^ Hagner, Patrick R.; Chiu, Hsiling; Chopra, Vivek S.; Colombo, Martino; Patel, Nisha; Estevez, Maria Ortiz; Waldman, Michelle F.; Loos, Remco; Towfic, Fadi; Gandhi, Anita K. (2 August 2022).
"Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL". Clinical Cancer Research. 28 (15): 3367–3377.
doi:
10.1158/1078-0432.CCR-21-3347.
PMC
9662945.
PMID
35583604.
-
^ Santiesteban, Daniela Y; Duncan, Aundrietta D; Mirza, Nadeem Q; Jacques, Vincent; DeWitt, Sheila; Iyer, Swami P. (15 November 2022).
"SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models". Blood. 140 (Supplement 1): 8865–8866.
doi:
10.1182/blood-2022-167495.
S2CID
254268049.
-
^ Ribrag, Vincent; Chavez, Julio C.; Boccomini, Carola; Kaplan, Jason; Chandler, Jason C.; Santoro, Armando; Corradini, Paolo; Flinn, Ian W.; Advani, Ranjana; Cassier, Philippe A.; Sangha, Randeep; Kenkre, Vaishalee P.; Isufi, Iris; Uttamsingh, Shailaja; Hagner, Patrick R.; Gandhi, Anita K.; Shen, Frank; Michelliza, Sophie; Haeske, Harald; Hege, Kristen; Pourdehnad, Michael; Kuruvilla, John (February 2022).
"Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma". EJHaem. 3 (1): 139–153.
doi:
10.1002/jha2.375.
PMC
9176062.
PMID
35846221.